3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Hematologic Diseases
1
Interventions
Brentuximab Vedotin
7
dacetuzumab
4
Lenalidomide
3
Doxorubicin
3
Dexamethasone
3
spartalizumab
2
lintuzumab
2
fludarabine
2
Vincristine
2
Rituximab
2
Rifampin
2
Prednisone
2
Gemcitabine
2
Cyclophosphamide
2
tanespimycin
1
sabatolimab
1
pomalidomide
1
pirtobrutinib
1
fludarabine phosphate
1
ficlatuzumab
1
daratumumab
1
Vinblastine
1
Thiotepa
1
TAS4464
1
Sertraline
1
R-CHOP protocol
1
Pam2CSK4 acetate and ODN M362 combination
1
Midazolam
1
Melphalan
1
LCL161
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Hematologic Diseases
×
CHR 2845
×
Clear all
NCT00820508
2011-11-28
CHR-2845-001
Chroma Therapeutics
Phase 1
Completed
18 enrolled